Alnylam Pharmaceuticals Rating Reiterated by Zacks (ALNY)
Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “neutral” rating restated by Zacks in a research report issued to clients and investors on Monday, Stock Ratings News reports. They currently have a $83.00 price objective on the stock. Zacks‘ price objective suggests a potential upside of 5.44% from the stock’s previous close.
Zacks‘ analyst wrote, “Alnylam’s fourth quarter 2013 loss of $0.51 per share was wider than the year-ago loss of $0.24 and the Zacks Consensus Estimate of a loss of $0.48 per share. We are nonetheless encouraged by Alnylam’s progress with its pipeline, especially the ATTR program. However, any negative news related to the pipeline will weigh heavily on the stock. We expect investor focus to remain on the development of the pipeline. Meanwhile, Alnylam’s deal with Sanofi is encouraging. The deal ensures continued pipeline progress apart from boosting Alnylam’s balance sheet. We see limited upside potential from current levels and hence maintain our Neutral stance on Alnylam.”
Alnylam Pharmaceuticals (NASDAQ:ALNY) traded down 3.48% on Monday, hitting $78.72. The stock had a trading volume of 767,753 shares. Alnylam Pharmaceuticals has a 52 week low of $21.60 and a 52 week high of $112.57. The stock’s 50-day moving average is $77.79 and its 200-day moving average is $61.93. The company’s market cap is $5.014 billion.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Wednesday, February 19th. The company reported ($0.51) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.45) by $0.06. The company had revenue of $10.80 million for the quarter, compared to the consensus estimate of $9.98 million. During the same quarter in the prior year, the company posted ($1.20) earnings per share. The company’s quarterly revenue was up 27.1% on a year-over-year basis. On average, analysts predict that Alnylam Pharmaceuticals will post $-2.11 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Needham & Company raised their price target on shares of Alnylam Pharmaceuticals from $65.00 to $84.00 in a research note on Friday. They now have a “buy” rating on the stock. Separately, analysts at JMP Securities raised their price target on shares of Alnylam Pharmaceuticals from $68.00 to $110.00 in a research note on Friday, January 31st. Finally, analysts at Deutsche Bank raised their price target on shares of Alnylam Pharmaceuticals from $80.00 to $108.00 in a research note on Friday, January 17th. They now have a “buy” rating on the stock. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $79.50.
Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) is a biopharmaceutical company developing therapeutics based on ribonucleic acid interface (RNAi).
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.